Curt Bradshaw's most recent trade in NeuBase Therapeutics Inc was a trade of 250,000 Employee stock option (right to buy) done . Disclosure was reported to the exchange on Dec. 1, 2020.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NeuBase Therapeutics Inc | Curt Bradshaw | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 250,000 | 250,000 | - | - | Employee stock option (right to buy) | |
| Arrowhead Pharmaceuticals ... | Curt Bradshaw | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 69.39 per share. | 19 Nov 2020 | 15,625 | 15,625 (0%) | 0% | 69.4 | 1,084,219 | Common Stock |
| Arrowhead Pharmaceuticals ... | Curt Bradshaw | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 68.73 per share. | 19 Nov 2020 | 15,625 | 0 (0%) | 0% | 68.7 | 1,073,906 | Common Stock |